Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Avammune Therapeutics Inc. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit. This structure shows a very direct and centralized prosecution path for the company's current active applications, with no distribution across multiple departments.
The busiest examiner for the portfolio is RICCI, CRAIG D, who is overseeing 1 pending office action. Given that the total number of pending actions is 1, this examiner is responsible for the company's entire active workload. This 1 to 1 ratio between the busiest examiner's pending cases and the total portfolio indicates that all current legal efforts are directed through a single individual. There is no variety in the examiner pool for this portfolio.
The presence of 1 distinct art unit suggests that the technical focus of the current filings is highly specific. Practitioners should be aware that there is no variety in examiner assignments or art unit oversight for the 1 pending office action. The prosecution remains focused within the Biotechnology & Pharmaceuticals sector under the guidance of RICCI, CRAIG D, requiring a strategy tailored to this specific official.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RICCI, CRAIG D | 1 | 53.7% | +52.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17760828 | 2-AMINO-S6-SUBSTITUTED THIOPURINE COMPOUNDS AS INHIBITORS OF THE ENPP1 PROTEIN | RICCI, CRAIG D | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17760828 | 2-AMINO-S6-SUBSTITUTED THIOPURINE COMPOUNDS AS INHIBITORS OF THE ENPP1 PROTEIN | RICCI, CRAIG D | 1611 | §102 | Final Rejection | — | Pending | Mar 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAvammune Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Craig D Ricci has the most, with 1 of Avammune Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.